君常乐
2021-06-30
这篇文章不错,转发给大家看
@新股小诸葛:
一天8家公司招股,怎么排序?
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":153542860,"tweetId":"153542860","gmtCreate":1625038792350,"gmtModify":1625038792350,"author":{"id":3583532798201114,"authorId":3583532798201114,"authorIdStr":"3583532798201114","name":"君常乐","avatar":"https://static.tigerbbs.com/cbef19f5689ab8b2d69123cc0e0aef58","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>\n这篇文章不错,转发给大家看</body></html>","htmlText":"<html><head></head><body>\n这篇文章不错,转发给大家看</body></html>","text":"这篇文章不错,转发给大家看","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/153542860","repostId":153679134,"repostType":1,"repost":{"magic":2,"id":153679134,"tweetId":"153679134","gmtCreate":1625022780000,"gmtModify":1625024884901,"author":{"id":3550637927571747,"authorId":3550637927571747,"authorIdStr":"3550637927571747","name":"新股小诸葛","avatar":"https://static.tigerbbs.com/7ba9f035f36c20133d5ae188299470fc","vip":8,"userType":8,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":461,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"一天8家公司招股,怎么排序?","extraTitle":"","html":"<html><head></head><body><p><span>今天新股很多,小诸葛就简单说说,直接给答案:</span></p> <p><strong><span>1</span><span>.康圣环球:</span></strong><span>特检中血液检测第一股,业绩还可以,但是其实增速和盈利能力上来看,还没有表现出来,虽然有第一股之称,但是多多少少有些瑕疵。</span></p> <p><strong><span>2</span><span>.腾盛博药:</span></strong><span>只做最难的药,基本上把能用的资源都用了,也跟药明系合作了,也有国际药企</span><span>GSK</span><span>的创始人和高管。一手入场费</span><span>11237</span><span>港币,价格</span><span>21-22.25</span><span>港币,一手</span><span>500</span><span>股,对应按照目前的热度,预计参与人数</span><span>20-40</span><span>万左右,预计一手中签率</span><span>5%-10%</span><span>左右,预计</span><span>60-80</span><span>手可中一手,预计乙头可中</span><span>5-7</span><span>手左右。乙头</span><span>600</span><span>手,</span><span>592</span><span>万港币,</span><span>20</span><span>倍孖展需本金约</span><span>34</span><span>万港币</span><span>.</span></p> <p><span>本次招股基石基本吃完,</span><span>Invesco</span><span>、</span><span>UBS</span><span>、常春藤、</span><span>AIHC</span><span>、博裕、红杉等,按中间价计算,占比约</span><span>49%</span><span>。</span></p> <p><strong><span>3</span><span>.医脉通:</span></strong><span>自带互联网属性,波动比较大,现在市场比较热的是它,可能有人把它定位成下一个医渡科技,财务增速快,想象空间大,给到估值溢价也很正常。一手入场费</span><span>13737</span><span>港币,价格</span><span>24.1-27.2</span><span>港币,一手</span><span>500</span><span>股,对应按照目前的热度,预计参与人数</span><span>20-40</span><span>万左右,预计一手中签率</span><span>10%-15%</span><span>左右,预计</span><span>60-80</span><span>手可中一手,考虑到热票较多,且医脉通募资较多,预计乙头可中</span><span>8</span><span>手左右。乙头</span><span>400</span><span>手,</span><span>549</span><span>万港币,</span><span>20</span><span>倍孖展需本金约</span><span>27.5</span><span>万港币</span><span>。</span></p> <p><span>本次招股基石基本吃完,</span><span>FRM</span><span>、富达、</span><span>Tencent</span><span>、</span><span>GIC</span><span>、</span><span>Matthews</span><span>、</span><span>OrbiMed</span><span>、</span><span>Springhill</span><span>等,按中间价计算,占比约</span><span>42.3%</span><span>。</span></p> <p><strong><span>4.</span><span>环球新材:</span></strong><span>在珠光材料是隐形冠军,就是市值小了点,基本面还是比较稳定的。我也会参与</span></p> <p><span><strong><span>如果非要去配比的话,康圣:腾盛:医脉通:环球新材,小诸葛个人配比2:4:3:1。</span></strong></span></p> <p><strong><span>推荐阅读:</span></strong></p> <p><strong>1.康圣环球:中国血液检测龙头即将上市</strong></p> <p><span><strong>2.康诺亚生物招股,又是满基石?</strong></span></p> <p></p> <p><span><strong>你的每个转发、赞和在看,我都喜欢!</strong></span></p></body></html>","htmlText":"<html><head></head><body><p><span>今天新股很多,小诸葛就简单说说,直接给答案:</span></p> <p><strong><span>1</span><span>.康圣环球:</span></strong><span>特检中血液检测第一股,业绩还可以,但是其实增速和盈利能力上来看,还没有表现出来,虽然有第一股之称,但是多多少少有些瑕疵。</span></p> <p><strong><span>2</span><span>.腾盛博药:</span></strong><span>只做最难的药,基本上把能用的资源都用了,也跟药明系合作了,也有国际药企</span><span>GSK</span><span>的创始人和高管。一手入场费</span><span>11237</span><span>港币,价格</span><span>21-22.25</span><span>港币,一手</span><span>500</span><span>股,对应按照目前的热度,预计参与人数</span><span>20-40</span><span>万左右,预计一手中签率</span><span>5%-10%</span><span>左右,预计</span><span>60-80</span><span>手可中一手,预计乙头可中</span><span>5-7</span><span>手左右。乙头</span><span>600</span><span>手,</span><span>592</span><span>万港币,</span><span>20</span><span>倍孖展需本金约</span><span>34</span><span>万港币</span><span>.</span></p> <p><span>本次招股基石基本吃完,</span><span>Invesco</span><span>、</span><span>UBS</span><span>、常春藤、</span><span>AIHC</span><span>、博裕、红杉等,按中间价计算,占比约</span><span>49%</span><span>。</span></p> <p><strong><span>3</span><span>.医脉通:</span></strong><span>自带互联网属性,波动比较大,现在市场比较热的是它,可能有人把它定位成下一个医渡科技,财务增速快,想象空间大,给到估值溢价也很正常。一手入场费</span><span>13737</span><span>港币,价格</span><span>24.1-27.2</span><span>港币,一手</span><span>500</span><span>股,对应按照目前的热度,预计参与人数</span><span>20-40</span><span>万左右,预计一手中签率</span><span>10%-15%</span><span>左右,预计</span><span>60-80</span><span>手可中一手,考虑到热票较多,且医脉通募资较多,预计乙头可中</span><span>8</span><span>手左右。乙头</span><span>400</span><span>手,</span><span>549</span><span>万港币,</span><span>20</span><span>倍孖展需本金约</span><span>27.5</span><span>万港币</span><span>。</span></p> <p><span>本次招股基石基本吃完,</span><span>FRM</span><span>、富达、</span><span>Tencent</span><span>、</span><span>GIC</span><span>、</span><span>Matthews</span><span>、</span><span>OrbiMed</span><span>、</span><span>Springhill</span><span>等,按中间价计算,占比约</span><span>42.3%</span><span>。</span></p> <p><strong><span>4.</span><span>环球新材:</span></strong><span>在珠光材料是隐形冠军,就是市值小了点,基本面还是比较稳定的。我也会参与</span></p> <p><span><strong><span>如果非要去配比的话,康圣:腾盛:医脉通:环球新材,小诸葛个人配比2:4:3:1。</span></strong></span></p> <p><strong><span>推荐阅读:</span></strong></p> <p><strong>1.康圣环球:中国血液检测龙头即将上市</strong></p> <p><span><strong>2.康诺亚生物招股,又是满基石?</strong></span></p> <p></p> <p><span><strong>你的每个转发、赞和在看,我都喜欢!</strong></span></p></body></html>","text":"今天新股很多,小诸葛就简单说说,直接给答案: 1.康圣环球:特检中血液检测第一股,业绩还可以,但是其实增速和盈利能力上来看,还没有表现出来,虽然有第一股之称,但是多多少少有些瑕疵。 2.腾盛博药:只做最难的药,基本上把能用的资源都用了,也跟药明系合作了,也有国际药企GSK的创始人和高管。一手入场费11237港币,价格21-22.25港币,一手500股,对应按照目前的热度,预计参与人数20-40万左右,预计一手中签率5%-10%左右,预计60-80手可中一手,预计乙头可中5-7手左右。乙头600手,592万港币,20倍孖展需本金约34万港币. 本次招股基石基本吃完,Invesco、UBS、常春藤、AIHC、博裕、红杉等,按中间价计算,占比约49%。 3.医脉通:自带互联网属性,波动比较大,现在市场比较热的是它,可能有人把它定位成下一个医渡科技,财务增速快,想象空间大,给到估值溢价也很正常。一手入场费13737港币,价格24.1-27.2港币,一手500股,对应按照目前的热度,预计参与人数20-40万左右,预计一手中签率10%-15%左右,预计60-80手可中一手,考虑到热票较多,且医脉通募资较多,预计乙头可中8手左右。乙头400手,549万港币,20倍孖展需本金约27.5万港币。 本次招股基石基本吃完,FRM、富达、Tencent、GIC、Matthews、OrbiMed、Springhill等,按中间价计算,占比约42.3%。 4.环球新材:在珠光材料是隐形冠军,就是市值小了点,基本面还是比较稳定的。我也会参与 如果非要去配比的话,康圣:腾盛:医脉通:环球新材,小诸葛个人配比2:4:3:1。 推荐阅读: 1.康圣环球:中国血液检测龙头即将上市 2.康诺亚生物招股,又是满基石? 你的每个转发、赞和在看,我都喜欢!","highlighted":1,"essential":1,"paper":2,"link":"https://laohu8.com/post/153679134","repostId":0,"isVote":1,"tweetType":1,"commentLimit":10,"symbols":["02162","02137","06616","02192","09960"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":1257,"xxTargetLangEnum":"ZH_CN"},"isVote":1,"tweetType":1,"viewCount":1524,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":25,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/153542860"}
精彩评论